Sugi Predict

Sugi Predict / Compounds / SCHEMBL315706

SCHEMBL315706

SCHEMBL315706

CC1COCCN1C(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ PIK3R1 P27986 5/20 0.39
▸ PIK3CA P42336 5/20 0.39
▸ HSD17B10 Q99714 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12021701 1.00 USP2 (0.53) USP2SMN1; SMN2CA12CA1CA2
SCHEMBL12021512 1.00 USP2 (0.53) USP2SMN1; SMN2CA12CA1CA2
SCHEMBL2114585 0.90 SMN1; SMN2 (0.46) USP2SMN1; SMN2CA12CA1CA2
SCHEMBL2114587 0.90 SMN1; SMN2 (0.46) USP2SMN1; SMN2CA12CA1CA2
SCHEMBL8099609 0.85 USP2 (0.51) USP2SMN1; SMN2CA12CA1CA2
SCHEMBL925405 0.83 USP2 (0.53) USP2SMN1; SMN2RECQLHSD17B10CHRM2
SCHEMBL12051038 0.83 USP2 (0.43) USP2SMN1; SMN2RECQLHSD17B10CHRM2
SCHEMBL315705 0.82 USP2 (0.51) USP2SMN1; SMN2CA12CA1CA2
SCHEMBL14410373 0.82 USP2 (0.51) USP2SMN1; SMN2RECQLHSD17B10CHRM2
SCHEMBL18047 0.82 USP2 (0.46) USP2SMN1; SMN2RECQLPIK3R1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118946566-A Heterocyclic compounds as ubiquitin-specific protease 7 inhibitors 阿尔麦克探索有限公司 2024-11-12 — — CN disclosed
CN-115991679-A 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer 伊忒欧斯比利时股份公司 2023-04-21 — — CN disclosed
EP-3092234-B1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2018-02-14 — — EP disclosed
WO-2017182418-A1 CONJUGATES COMPRISING RIPK2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-10-26 — — WO disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 — — US disclosed
US-20170088527-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2017-03-30 — — US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 — — US disclosed
US-20160317504-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2016-11-03 — — US disclosed
US-9416115-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCINECES, INC. (US) 2016-08-16 — — US disclosed
US-20150175560-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2015-06-25 — — US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 — — US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 — — US disclosed
EP-2399577-A1 Use of N-containing spirocompounds for the enhancement of cognitive function Adolor Corporation (US) 2011-12-28 — — EP disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 — — US disclosed
US-7745438-B2 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors ELI LILLY AND COMPANY (US) 2010-06-29 — — US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed
CN-100448874-C N-aroyl cyclic amines SMITHKLINE BEECHAM PLC (GB) 2009-01-07 — — CN disclosed
US-20070225267-A1 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 — — US disclosed
CN-1633433-A N-aroyl cyclic amines SMITHKLINE BEECHAM PLC (GB) 2005-06-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170088527-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS CACNA1A, KCNJ2, KCNH2 USP2 4716/4885SMN1; SMN2 1725/4885CA12 4205/4885
US-20070225267-A1 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors BACE1, BACE2, APP USP2 3271/4885SMN1; SMN2 479/4885CA12 4167/4885
US-20150175560-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS CACNA1A, KCNJ2, KCNH2 USP2 4716/4885SMN1; SMN2 1725/4885CA12 4205/4885
US-20160317504-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS CACNA1A, KCNJ2, KCNH2 USP2 4716/4885SMN1; SMN2 1725/4885CA12 4205/4885
US-20100317652-A1 Compounds Useful In Therapy AVPR1A, AVPR1B, AVPR2 USP2 4525/4885SMN1; SMN2 4519/4885CA12 3814/4885
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN USP2 4800/4885SMN1; SMN2 3500/4885CA12 3399/4885
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 USP2 1496/4885SMN1; SMN2 3601/4885CA12 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.